Skip to main content
Premium Trial:

Request an Annual Quote

Progenika Biopharma Lands CE Mark for NGS Familial Hypercholesterolemia Test

NEW YORK (GenomeWeb) – Grifols subsidiary Progenika Biopharma today announced it has received the CE mark for its Seqpro Lipo IS next-generation sequencing-based diagnostic assay for familial hypercholesterolemia.

The kit is the first NGS-based test for the disease, which affects roughly one in 300 people and is characterized by high levels of LDL cholesterol, the firm said in a statement. The test looks at six genes associated with the condition: LDLR, APOB, PCSK9, APOE, STAP1, and LDLRAP1. Progenika said that it can run 96 patient samples at once on the Illumina MiSeq sequencer, which reduces operating time.

Progenika added that its CLIA-certified US laboratory has provided genotyping services in clinical trials for anti-PCSK9 drugs for familial hypercholesterolemia.

Last year, Progenika received CE-IVD certification for its ID Core XT bead array-based molecular blood group typing assay.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.